SCHEMBL4112467

SCHEMBL4112467

Cc1ccc(NC(=O)Nc2cccc(C#N)c2)cc1Cl

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.68
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
ALDH1A1 P00352 2/20 0.68
SMN1; SMN2 Q16637 4/20 0.67
KCNJ6 P48051 2/20 0.63
KCNJ5 P48544 2/20 0.63
KCNJ3 P48549 2/20 0.63
NPC1 O15118 4/20 0.62
RAB9A P51151 4/20 0.62
GAA P10253 1/20 0.55
ALOX15 P16050 1/20 0.55
CASP7 P55210 1/20 0.55
HSD17B10 Q99714 1/20 0.55
CA2 P00918 1/20 0.53
NSD2 O96028 1/20 0.53
STING1 Q86WV6 1/20 0.50
P2RX1 P51575 1/20 0.50
KDM4E B2RXH2 1/20 0.50
EPHX2 P34913 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4113462 0.87 MAPT (0.73) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL2785113 0.87 SMN1; SMN2 (0.67) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL29580531 0.84 MAPT (0.87) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL30606801 0.84 MAPT (0.87) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4125166 0.84 MEN1 (0.68) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4117070 0.83 MAPT (0.80) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL30577265 0.82 SMN1; SMN2 (0.81) MAPTMEN1KMT2ASMN1; SMN2KCNJ6
SCHEMBL27371332 0.81 MEN1 (0.72) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL7248947 0.81 MAPT (1.00) MAPTMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4111390 0.81 SMN1; SMN2 (0.75) MAPTMEN1KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 MAPT 1654/4885MEN1 3273/4885KMT2A 2807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.